SLC17A1 and metabolic dysfunction-associated steatotic liver disease: For instance, Jiang et al. have shown that Arbutin can ameliorate high‐fat diet (HFD)‐induced NAFLD via the FTO/SLC7A11 pathway; the mechanism of action involves inhibition of Fatty Acid Transcriptional Repressor (FTO), which in turn enhances m6A methylation of Solute Carrier Family 7 Member 11 (SLC7A11); this process upregulates SLC7A11 expression and ultimately inhibits ferroptosis, offering a novel approach and theoretical foundation for NAFLD treatment [259, 260, 261, 262].